Actelion to host Conference Call / Audiocast on the positive GRIPHON Study Results Montag, 16. Juni 2014 - 06:56

Dear member of the investment community,

Actelion Ltd will host a Conference Call / Audiocast on the positive GRIPHON Study Results today, on Monday, 16 June 2014, at 14.00 CEST / 13.00 BST / 08.00 a.m. EDT.

The company announced today that selexipag met the primary endpoint in the pivotal Phase III GRIPHON outcome in patients with pulmonary arterial hypertension.

Actelion will present the top-line results and be available for Q&A.

Management will be represented by:

• Jean-Paul Clozel (Chief Executive Officer)
• Guy Braunstein (Head of Global Clinical Development)
• Andrew Weiss (Head Investor Relations & Corporate Communications)

Date/Time:

Conference Call Connect #:

Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start. 

Participant's mode:

Listen-Only with possibility to open individual lines during Q&A session. Participants will be asked for their Name and Company.

Audiocast Access:

Audiocast participants should visit the Actelion website www.actelion.com 10-15 minutes before the conference is due to start. 

Participant's mode:

Listen only

Audiocast Replay:

The archived Investor Audiocast will be available for replay through http://www.actelion.com approximately 60 minutes after the call has ended.

For further information please contact:

Andrew Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications 
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil      
+41 61 565 62 62
http://www.actelion.com